3 Significant survival advantage with anticoagulation without the use of inferior vena cava filters in elderly cancer patients with venous thromboembolism

2006 ◽  
Vol 60 ◽  
pp. S24-S25
Author(s):  
M. Barginear ◽  
M.L. Lesser ◽  
I. Shapira ◽  
T. Bradley ◽  
D.R. Budman
2019 ◽  
Vol 16 (5) ◽  
pp. S214-S226 ◽  
Author(s):  
Jeet Minocha ◽  
Aaron M. Smith ◽  
Baljendra S. Kapoor ◽  
Nicholas Fidelman ◽  
Thomas R. Cain ◽  
...  

2008 ◽  
Vol 15 (3) ◽  
pp. 263-269 ◽  
Author(s):  
Myra F. Barginear ◽  
Martin Lesser ◽  
Meredith Lukin Akerman ◽  
Marianna Strakhan ◽  
Iuliana Shapira ◽  
...  

2010 ◽  
Vol 4 (3) ◽  
pp. 147-157 ◽  
Author(s):  
Rachna Raman ◽  
Philip D. Leming ◽  
Manish Bhandari ◽  
Daniel Long ◽  
Michael B. Streiff

2016 ◽  
Vol 9 (3) ◽  
pp. 102-105 ◽  
Author(s):  
Lodewyk E Du Plessis ◽  
Ben W Mol ◽  
John M Svigos

Background Pregnant women with venous thromboembolism are traditionally managed with anticoagulation, but inferior vena cava filters are an alternative. We balanced risks and benefits of an inferior vena cava filter in a decision analysis. Methods We constructed a decision model to compare in pregnant women with VTE the outcome of (1) inferior vena cava filter and anticoagulant treatment versus (2) anticoagulant treatment only. Results Assuming a 63% risk reduction from an inferior vena cava filter (baseline mortality rate of venous thromboembolism of 0.5%), 318 women would need to be treated with inferior vena cava filters to prevent one venous thromboembolism related maternal death. Sensitivity analyses indicated that at a mortality rate of 0.5% the risk reduction from inferior vena cava filters needed to be 80%, while at a mortality rate of 2% a risk reduction of 20% would justify inferior vena cava filters. Conclusions In view of their potential morbidity, inferior vena cava filters should be restricted to pregnant woman at strongly increased risk of recurrent venous thromboembolism.


JAMA ◽  
2019 ◽  
Vol 321 (10) ◽  
pp. 1007
Author(s):  
Tobias Tritschler ◽  
Noémie Kraaijpoel ◽  
Philip S. Wells

2019 ◽  
Vol 03 (01) ◽  
pp. 037-043
Author(s):  
Harit Kapoor ◽  
Driss Raissi

AbstractInferior vena cava filters (IVCFs) remain an indispensable part of an interventionalist's toolbox. Increased recognition of filter-related complications, largely from off-label use and casual approach to filter retrieval, has led to tremendous uncertainty surrounding their use. More stringent regulations on their use and development of newer and safer anticoagulants are gradually changing their role in the management of venous thromboembolism. Herein, the authors review the current role of IVCFs, indications for their use and retrieval, as well as filter-related complications.


Sign in / Sign up

Export Citation Format

Share Document